Immunotherapeutic and Targeted Approaches in Multiple Myeloma by Nadeem O, Tai YT, Anderson KC

Get full text

Novel Approaches to Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent Approvals of Belantamab Mafodotin and Selinexor by Joseph NS, Tai YT, Anderson KC, Lonial S

Get full text

Lenalidomide for the treatment of relapsed and refractory multiple myeloma by van de Donk NW, Görgün G, Groen RW, Jakubikova J, Mitsiades CS, Hideshima T, Laubach J, Nijhof IS, Raymakers RA, Lokhorst HM, Richardson PG, Anderson KC

Get full text

Lysine demethylase 5A is required for MYC-driven transcription in multiple myeloma by Ohguchi, H, Park, PMC, Wang, T, Gryder, BE, Ogiya, D, Kurata, K, Zhang, X, Li, D, Pei, C, Masuda, T, Johansson, C, Wimalasena, VK, Kim, Y, Hino, S, Usuki, S, Kawano, Y, Samur, MK, Tai, Y-T, Munshi, NC, Matsuoka, M, Ohtsuki, S, Nakao, M, Minami, T, Lauberth, S, Khan, J, Oppermann, U, Durbin, AD, Anderson, KC, Hideshima, T, Qi, J

Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma by Kurata, K, James-Bott, A, Tye, MA, Yamamoto, L, Samur, MK, Tai, Y-T, Dunford, J, Johansson, C, Senbabaoglu, F, Philpott, M, Palmer, C, Ramasamy, K, Gooding, S, Smilova, M, Gaeta, G, Guo, M, Christianson, JC, Payne, NC, Singh, K, Karagoz, K, Stokes, ME, Ortiz, M, Hagner, P, Thakurta, A, Cribbs, A, Mazitschek, R, Hideshima, T, Anderson, KC, Oppermann, U

Genomic landscape and chronological reconstruction of driver events in multiple myeloma by Maura, F, Bolli, N, Angelopoulos, N, Dawson, KJ, Leongamornlert, D, Martincorena, I, Mitchell, TJ, Fullam, A, Gonzalez, S, Szalat, R, Abascal, F, Rodriguez-Martin, B, Samur, MK, Glodzik, D, Roncador, M, Fulciniti, M, Tai, YT, Minvielle, S, Magrangeas, F, Moreau, P, Corradini, P, Anderson, KC, Tubio, JMC, Wedge, DC, Gerstung, M, Avet-Loiseau, H, Munshi, N, Campbell, PJ